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Abstract. Regio- and stereoselective reductions of several 
diketones to afford enantiopure hydroxy ketones or diols 
were accomplished using isolated alcohol dehydrogenases 
(ADHs). Results could be rationalised taking into account 
different (promiscuous) substrate-binding modes in the 
active site of the enzyme. Furthermore, interesting natural 
cyclic diketones were also reduced with high regio- and 
stereoselectivity. 
Some of the 1,2- and 1,3-diketones used in this study were 
reduced employing a low excess of the hydrogen donor (2-
propanol) due to the quasi-irreversibility of these ADH-
catalysed processes. Thus, using less quantity of co-
substrate, scale-up could be easily achieved. 
Keywords: alcohol dehydrogenases; hydroxy ketones; 
diols; hydrogen transfer; quasi-irreversible reduction 
 
1 Introduction 
For decades, synthetic organic chemists have devoted 
their efforts in developing new and versatile 
protecting-deprotecting strategies in order to 
selectively modify similar reacting moieties in the 
same molecule. Hence, considering the loss of the 
yields and the laborious separation techniques in 
multistep protocols, a different approach is always 
desired. Biocatalysis has become a powerful tool for 
highly stereo- and regioselective transformations due 
to the intrinsic chirality of enzymes.
[1]
 In particular, 
biocatalysed regioselective transformations using 
hydrolases have widely been described in the 
bibliography,
[1,2]
 while using oxidoreductases have 
less frequently been performed. 
It is well established that enantioenriched anti diols 
can be readily available through epoxide ring opening 
starting from the suitable oxirane.
[3]
 On the other 
hand, syn diols can be obtained via osmium-catalysed 
oxidation of olefins, among other methods.
[4]
 
Enantioselective epoxide hydrolase-catalysed oxirane 
opening leads to the preparation of anti diols,
[5]
 but 
the intrinsic handicap of the maximum 50% yield still 
remains. Aldolases have also been employed to 
afford syn- or anti-derivatives, although the 
reversibility of these processes appears as the main 
drawback.
[6]
 
However, the use of alcohol dehydrogenases 
(ADHs, also called ketoreductases or carbonyl 
reductases) applied to the synthesis of such important 
compounds has been scarcely developed. In the last 
few years, the use of purified or overexpressed ADHs 
have gained increasing relevance.
[7-14]
 The 
requirement of expensive nicotinamide cofactors 
[NAD(P)H] in those processes has slowed down their 
industrial applicability, although the use of several 
methodologies to recycle the cofactor have greatly 
improved the efficacy of these biotransformations.
[9-
18]
 In the particular case of the synthesis of 
enantiopure hydroxy ketones and/or diols starting 
from the corresponding diketones employing isolated 
ADHs, there are few examples available in the 
literature.
[19-26]
 In other cases plants or micro-
organisms are employed,
[27-32]
 frequently affording a 
mixture of stereo- and regioisomers due to the action 
of several enzymes with different and/or opposite 
selectivities. These derivatives are important building 
blocks of many natural compounds,
[33,34]
 such as 
pheromones
[35,36]
 or antitumor agents like 
discodermolide.
[37]
 As a result, they are used as chiral 
precursors for fine chemicals in the flavour and 
fragrance-, agrochemical-, and pharmaceutical 
industry.
[38]
 α-Hydroxy ketones (also called acyloins), 
constitute well-known derivatives for the synthesis of 
1,2-amino alcohols through diastereoselective 
reductive amination.
[39]
 Furthermore, short-chain 
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diols can be employed as starting materials for chiral 
polymers
[40]
 or as backbone for chiral ligands applied 
to asymmetric transition metal catalysis.
[41]
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Figure 1. Diketones employed in this study. 
Herein we present a stereo- and regioselective 
ADH-catalysed reduction of several diketones of 
interest (Figure 1) with excellent ees and des, using 
internal recycling of cofactor (‘substrate-coupled’ 
approach). We will focus on the different substrate 
recognition modes in order to explain the 
experimental results obtained, and we will show for 
the first time the quasi-irreversible reduction 
concept
[42]
 catalysed by ADHs applied to 1,2- and 
1,3-diketones. 
2 Results and Discussion 
As a first step, several diketones (Figure 1) were 
chosen as suitable substrates to be reduced by 
commercial ADHs.
[43]
 Thus, 1,2- (1a-c), 1,3- (1d-e), 
and 1,4-diketones (1f) were firstly used in order to 
study the acceptance of the tested enzymes (Scheme 
1 and Table 1). Lactobacillus brevis ADH 
(LBADH),
[44]
 alcohol dehydrogenase from 
Rhodococcus ruber (ADH-‘A’),[45] and ADH from 
Thermoanaerobacter sp. (ADH-T)
[46]
 were selected 
as biocatalysts to perform the corresponding 
reductions using an excess of 2-propanol as hydrogen 
donor, through a ‘substrate-coupled’ or ‘biocatalytic 
hydrogen transfer’ approach.[14] The first enzyme 
shows a perfect anti-Prelog selectivity, this is, it 
catalyses the transfer of the hydride to the carbonyl 
moiety through its si face, while the second and third 
ADHs display an excellent Prelog profile. 
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Scheme 1. Regio- and stereoselective reduction of 1,2-, 1,3-, and 1,4-diketones using ADHs and 2-propanol. 
Table 1. ADH-catalysed reduction of diketones 1a-f with 2-propanol.
[a]
 
Entry Substrate ADH 2 [%]
[b]
 e.e. [%]
[c]
 3 [%]
[b]
 e.e. [%]
[c]
 4 [%]
[b]
 d.e. [%]
[c]
 e.e. [%]
[c]
 
1 1a LBADH 26 >99 (R) 3 99 (R) 69 91 (2R,3R) >99 
2 1a ADH-‘A’ 68 >99 (S) -- -- 32 62 (2S,3R) >99 
3 1a ADH-T 3 99 (S) 6 66 (R) 89 74 (2S,3R) >99 
4 1b LBADH 92 >99 (R) -- -- 6 99 (2R,3S) >99 
5 1b ADH-‘A’ 49 >99 (S) 2 99 (R) 46 95 (2S,3R) >99 
6 1b ADH-T 3 99 (S) 3 99 (R) 91 96 (2S,3R) >99 
7 1c LBADH 42 >99 (R) -- -- 10 99 (2R,3S) >99 
8 1c ADH-‘A’ 4 99 (S) -- -- 49 99 (2S,3R) >99 
9 1c ADH-T -- -- -- -- 62 99 (2S,3R) >99 
10 1d LBADH >97 >99 (R) -- -- -- -- -- 
11 1d ADH-‘A’ >97 >99 (S) -- -- -- -- -- 
12 1e LBADH >97 >99 (R) -- -- -- -- -- 
13 1e ADH-‘A’ >97 >99 (S) -- -- -- -- -- 
14 1f
[d]
 LBADH 25 >99 (R) -- -- -- -- -- 
15 1f
[d]
 ADH-‘A’ 60 >99 (S) -- -- -- -- -- 
16 1f
[d]
 ADH-T 62 >99 (S) -- -- -- -- -- 
[a]
 Reaction conditions: the corresponding diketone (1a-f, 100 mM) was added to the 50 mM Tris.HCl buffer pH 7.5 with 
the corresponding cofactor (1 mM) and 2-propanol (5% v v
-1
). 
[b]
 Measured by GC. 
[c]
 Calculated by chiral GC. 
[d]
 Less 
than 5% of a by-product was formed. 
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Scheme 2. Promiscuous binding-modes of diketones 1a-c and hydroxy ketones 2a-c in the active site of alcohol 
dehydrogenases: LBADH (binding-modes A and B); and ADH-‘A’ and ADH-T (binding-modes C and D). 
As can be noted, these ADHs accepted all the 
tested substrates although showing different 
behaviour. Thus, with diketone 1a, LBADH mainly 
afforded enantiopure syn derivative 2R,3R-4a (entry 
1), while ADH-‘A’ mainly provided enantiopure 
hydroxy ketone S-2a (entry 2) and ADH-T anti diol 
2S,3R-4a (entry 3). For the other 1,2-diketones 1b 
and 1c, LBADH showed a high preference for the 
regio- and stereoselective reduction of the carbonyl 
moiety at position 2, providing R-2b-c and a small 
quantity of anti diols 2R,3S-4b-c (entries 4 and 7). 
Meanwhile, Prelog biocatalysts allowed to obtain 
enantiopure anti diols 2S,3R-4b and 2S,3R-4c (entries 
6, 8, and 9). On the other hand, the reduction of 
diketone 1b with ADH-‘A’ afforded 49% of the 
enantiopure hydroxy ketone S-2b (entry 5). 
Looking at these results, it was obvious that the 
substrate structure greatly influenced the ADH-
catalysed reductions. For instance, LBADH mainly 
provided the unexpected syn diol 4a starting from 
diketone 1a, but when the substrate presented an 
additional methylene group in the alkyl chain (1b), 
hydroxy ketone 2b resulted in the main product and 
enantiopure anti diol 4b as minor product. Especially 
the formation of syn-4a was very remarkable since 
this enzyme has always been described as a perfect 
anti-Prelog enzyme.
[44]
 These data can be explained 
on basis of the promiscuous substrate binding of 1,2-
diketones at the active site of the enzyme (Scheme 2). 
Thus, these substrates possess two reactive positions, 
and therefore different binding-modes can be 
involved. For 1,2-diketones such as 1a-c, the 
carbonyl moiety at position 2 will be reduced 
following the standard fashion, that is, with the 
methyl group located in the small pocket and the 
ethylcarbonyl moiety in the big one. The conflict 
arises when ketone at position 3 is also reduced. 
Since location of the nicotinamide cofactor is well 
defined in the active site of ADHs,
[47]
 the hydride 
attack will take place through the same side, but two 
possible substrate orientations can exist: i) a similar 
one as the previously described, locating the 
hydroxyethyl group into the small binding-site and 
the ethyl moiety into the bigger site, thus affording 
the corresponding anti diols 4a-c (Scheme 2, binding-
modes A and C), or ii) the opposite substrate-binding 
providing the syn derivatives (Scheme 2, binding-
modes B and D). Depending on the pockets size of 
the biocatalyst, one mode will be favoured at the 
expense of the second one, and therefore different 
regio- and stereoisomer ratios will be obtained. 
From the obtained results, LBADH favoured the 
opposite disposition of hydroxy ketone 2a with 
regards to diketone 1a (Scheme 2, mode A), while for 
alcohols 2b-c a similar binding was preferred 
(Scheme 2, mode B). For 2b-c, since in the reverse 
binding-mode a propyl or a butyl moiety, respectively, 
should be located in the small pocket, this biocatalyst 
was not able to afford the corresponding syn diols. 
The hydroxyethyl group already seems to crowd the 
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small pocket of this ADH due to the low conversions 
obtained (less than 10%) for 4b-c (Table 1, entries 4 
and 7). On the other hand, ADH-‘A’ and ADH-T 
always preferred a similar disposition for 1a-c and 
2a-c placing the larger acyl chain into the bigger 
binding-site (Scheme 2, mode C), thus mainly 
affording the corresponding anti diols 4a-c. As larger 
the difference between the acyl chain and the 
hydroxyethyl moiety was, better the des favouring the 
anti derivatives were (Table 1, compare entries 2-3 
with 5-6 and 8-9). 
A clearer scenario appeared when 1,3- or 1,4-
diketones (1d-f) were subjected to the hydrogen 
transfer conditions (Table 1, entries 10 to 16). ADHs 
showed perfect regio- and stereoselectivity achieving 
the reduction of the carbonyl moiety at position 2 to 
afford enantiopure R-2d-f (in the case of LBADH) or 
S-2d-f (in the case of ADH-‘A’ and ADH-T) alcohols. 
Diketone 1f was less well accepted, obtaining 
moderate (with LBADH) or good conversions (with 
both Prelog enzymes). In this case another by-product 
(less than 5%) was formed. 
The selective modification of natural compounds 
in order to obtain novel derivatives with enhanced 
biological activities is a difficult task which organic 
chemists must often face.
[48,49]
 In our particular case, 
the natural product 6-acetyl-2,2-dimethyl-2,3-
dihydro-4H-chromen-4-one (1g) and the derivative 1-
(5-acetyl-2-methoxyphenyl)-3-methylbut-2-en-1-one 
(1h) were also chosen as substrates to study the regio- 
and stereoselectivity in the bioreduction processes 
catalysed by isolated ADHs (Table 2). The former 
was isolated from Ophryosporus axilliflorus (Griseb.) 
Hieron (Asteraceae). These and other related 
compounds showed anti-inflammatory activity.
[50]
 
Previous reductions of diketone 1g using plants were 
reported.
[27,51]
 It remained clear that LBADH was not 
a suitable enzyme to perform these bioreductions due 
to low conversions (entries 1 and 4). This is in 
concordance with the small active site of this 
biocatalyst. On the contrary, ADH-‘A’ and ADH-T 
were able to regioselectively reduce both substrates 
on the acetyl moiety (Ca) affording highly pure (S)-2g 
and 2h alcohols (entries 2, 3, 5 and 6). 
Table 2. ADH-catalysed reduction of natural compounds 
1g-h with 2-propanol.
[a]
 
Entry Substrate ADH 2 [%]
[b]
 e.e. [%]
[c]
 
1 1g LBADH 9 >99 (R) 
2 1g ADH-‘A’ 90 94 (S) 
3 1g ADH-T 86 90 (S) 
4 1h LBADH 3 n. d. 
5 1h ADH-‘A’ 95 >99 (S) 
6 1h ADH-T 45 >99 (S) 
[a]
 Reaction conditions: the corresponding diketone (1g-h, 
50 mM) was added to the 50 mM Tris.HCl buffer pH 7.5 
with the corresponding cofactor (1 mM) and 2-propanol 
(5% v v
-1
). 
[b]
 Measured by GC. 
[c]
 Calculated by chiral 
HPLC. n. d. not determined. 
Until this point, we were pleased to find out that 
different kind of diketones could regio- and 
stereoselectively be reduced by the tested ADHs. 
Having in mind the scale-up of these processes, we 
tried to perform the bioreductions at lower co-
substrate concentration, using less harmful conditions 
for the biocatalyst and maximising the atom 
efficiency
[52]
 of the process. We envisaged the 
possible irreversibility in the reduction of 1,2- and 
1,3-diketones since it has previously been described 
that 1-chloro-2-propanol
[42]
 cannot be oxidised by 
ADHs due to an intramolecular H-bond interaction 
between the hydroxyl group and the halogen atom.
[53]
 
Thus, 1,2- or 1,3-diketones could quasi-irreversibly 
be reduced since it is well known that the 
corresponding hydroxy ketones show a strong 
intramolecular interaction via H-bonding network 
(Figure 2).
[54]
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Figure 2. Intramolecular H-bond interactions in 1,2- and 
1,3-hydroxy ketones. 
In order to demonstrate this fact,
[55]
 we repeated 
the LBADH catalysed reduction of diketones 1b, 1d, 
and 1e employing different concentrations of 2-
propanol (from 2 equiv. to 10 equiv.), and results 
were compared with that obtained in the case of a 
non-activated ketone such as 2-octanone (1i). As can 
be noticed (Table 3), diketones were reduced into the 
corresponding hydroxy ketones (c >90%) even at low 
2-propanol concentration (entries 1, 4 and 7). On the 
contrary, for ketone 1i (entry 10) conversion was 
67% due to the similar equilibrium constants between 
the 2-octanone/2-octanol and acetone/2-propanol 
pairs.
[56]
 
Table 3. LBADH-catalysed reduction of 1,2- (1b), 1,3-
diketones (1d-e) and 2-octanone (1i), using different 
concentrations of 2-propanol.
[a]
 
Entry Substrate [2-propanol] [M] 2 [%]
[b]
 
1 1b 0.2 94 
2 1b 0.5 95 
3 1b 1 97 
4 1d 0.2 92 
5 1d 0.5 91 
6 1d 1 94 
7 1e 0.2 95 
8 1e 0.5 94 
9 1e 1 92 
10 1i 0.2 67 
[a]
 Reaction conditions: the corresponding diketone (100 
mM) was added to the 50 mM Tris.HCl buffer pH 7.5 with 
the corresponding cofactor (1 mM) and 2-propanol (200 
mM-1M). 
[b]
 Measured by GC. 
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Since a small amount of 2-propanol (2 equiv.) can 
be employed to quantitatively reduce this type of 
substrates, enantiopure (R)-alcohols 2b, 2d, and 2e 
were prepared on a higher scale starting from 25 mg 
of the corresponding diketones with isolated yields 
higher than 80%. 
3 Conclusions 
The bioreduction of diketones has not been 
extensively studied,
[19-26]
 and in several cases 
microorganisms or plants
[27-32]
 were used for this 
purpose. Thus, the obtained results in terms of regio- 
and stereoselectivity usually remained unclear. 
Herein we have shown the bioreduction of several 
diketones of interest catalysed by isolated alcohol 
dehydrogenases. With the advantage of using a single 
enzyme, we have proposed that in reductions of 1,2-
diketones, these substrates can be suited within the 
active site of the enzyme in two different orientations 
depending on the size of the enzyme pockets. Hence, 
just by choosing the proper catalyst, syn or anti 
products could be obtained. For instance, due to its 
small binding-site, LBADH presents a promiscuous 
binding for the diketone 1a and the hydroxy ketone 
intermediate to afford the corresponding syn-diol. On 
the other hand, ADH-‘A’ and ADH-T favour a 
similar recognition mode for both species, thus 
mainly providing the anti-derivatives. This is an 
elegant example of enzyme-based stereocontrol.
[57]
 In 
the case of the other diketones studied, perfect regio- 
and stereoselectivity was achieved obtaining the 
corresponding enantiopure hydroxy ketones. 
In addition, it has been demonstrated that 1,2- or 
1,3-diketones can be reduced via ADH-catalysed 
hydrogen transfer using quasi-irreversible 
conditions,
[42]
 this is, employing a low excess of the 
required co-substrate (2-propanol). This is due to the 
difficulty of the enzyme to oxidise backwards the 
formed hydroxy ketone due to an intramolecular H-
bond interaction between the hydroxyl and the 
remaining carbonyl moiety. Since a lower amount of 
the hydrogen donor (usually used in a huge excess) is 
needed, the scale-up of the ADH-catalysed reductions 
of such compounds is feasible. 
Experimental Section 
General. Alcohol dehydrogenases and ketones 1a-1f, 1i 
were purchased from commercial sources. Ketone 1g was 
isolated from aerial parts of Ophryosporus axilliflorus 
(Griseb.) Hieron according to Favier et al.
[50]
 The same 
procedure also afforded the diketone 1-(5-acetyl-2-
hydroxyphenyl)-3-methylbut-2-en-1-one which was 
methylated by classical methods (Me2SO4, K2CO3, under 
acetone reflux, 2 h) to obtain 1h. Racemic alcohols 2a-h, 
3a-c and 4a-c were purchased or synthesised by 
conventional reduction from the corresponding ketones 
(NaBH4, MeOH, 0 ºC or room temperature). All other 
reagents and solvents were of the highest quality available. 
1 unit (U) of ADH reduces 1.0 μM of acetophenone to 1-
phenylethanol per minute at pH 7.5 and 30 ºC in the 
presence of NAD(P)H. Flash chromatography was 
performed using silica gel 60 (230-400 mesh). 
General protocol for the biocatalytic reduction of 
diketones employing ADHs and 2-propanol. In a 1.5 mL 
Eppendorf vial, 3 U of ADH (Lactobacillus brevis ADH, 
Rhodococcus ruber ADH-‘A’, or Thermoanaerobacter sp. 
ADH) in Tris.HCl buffer [50 mM, pH 7.5, 1 mM 
NAD(P)H, 1 mM MgCl2 for LB-ADH] were mixed with 2-
propanol (32 µL, 5% v v
-1
) and the corresponding diketone 
(1a-1f, and 1i, 100 mM; 1g-1h, 50 mM). Reactions were 
shaken at 30 ºC and 120 rpm for 24 h and stopped by 
extraction with ethyl acetate (2 x 0.5 mL). The organic 
layer was separated by centrifugation (2 min, 13000 rpm) 
and dried (Na2SO4). Conversions and enantiomeric 
excesses of the corresponding alcohols were determined by 
GC or HPLC analysis on an achiral or a chiral stationary 
phase, respectively (see Supporting Information). 
General protocol for the biocatalytic reduction of 
diketones employing LBADH with different 
concentrations of 2-propanol. In a 1.5 mL Eppendorf vial, 
3 U of LBADH in Tris.HCl buffer (50 mM, pH 7.5, 1 mM 
NADPH, 1 mM MgCl2) were mixed with 2-propanol (200 
mM-1 M) and the corresponding diketone (1b, 1d, 1e or 1i, 
100 mM). Reactions were shaken at 30 ºC and 120 rpm for 
24 h and stopped by extraction with ethyl acetate (2 x 0.5 
mL). The organic layer was separated by centrifugation (2 
min, 13000 rpm) and dried (Na2SO4). Conversions were 
determined by GC analysis on an achiral stationary phase 
(see Supporting Information). 
Representative example for biocatalytic reduction of a 
diketone: preparation of (R)-2d. In a 5 mL screw-capped 
tube 5 U of LBADH in Tris.HCl buffer (1.8 mL, 50 mM, 
pH 7.5, 1 mM NADPH, 1 mM MgCl2) were mixed with 2-
propanol (27.5 μL, 0.36 mmol) and 1d (28 μL, 0.18 mmol). 
Reactions were shaken at 30 ºC and 120 rpm for 24 h and 
stopped by extraction with ethyl acetate (3 x 1 mL). The 
organic layer was separated by centrifugation (2 min, 
13000 rpm) and dried (Na2SO4). Alcohol 2d was purified 
by flash chromatography (petroleum ether:EtOAc 4:1) 
obtaining thus 21.5 mg (83%) of enantiopure (R)-2d: 
colourless oil; [α]D
20
 -13.7 (c 1.5 in CHCl3); IR (neat) 3420, 
2960, 2874, 1707, 1467, 1370, and 1125 cm
-1
; 
1
H-NMR 
(CDCl3, 300 MHz) δ 0.92 (d, 6H, H7, 
3
JHH 6.6 Hz), 1.18 (d, 
3H, H1, 
3
JHH 6.4 Hz), 2.07-2.20 (m, 1H, H6), 2.30 (d, 2H, 
H5, 
3
JHH 6.8 Hz), 2.48 (dd, 1H, H3, |
2
JHH| 17.8 
3
JHH 8.8 Hz), 
2.59 (dd, 1H, H3, |
2
JHH| 17.8 
3
JHH 3.1 Hz), and 4.22 (m, 1H, 
H2); 
13
C-NMR (CDCl3, 75.5 MHz) δ 22.2 (C1), 22.4 (2C, 
C7), 24.5 (C6), 50.8 (C3 or C5), 52.4 (C3 or C5), 63.7 (C2), 
and 212.2 (C4); MS (APCI
+
): m/z (%) = 144 (3) [M]
+
, 129 
(6) [M-CH3]
+
, 126 (8) [M-H2O]
+
, 111 (22), 87 (42), 69 
(61), 57 (80), and 43 (100). 
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